RUNX2

Across TCGA pan-cancer cohorts, RUNX2 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of RUNX2’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where RUNX2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RUNX2 is over-expressed in tumor, although a few such as PRAD show the opposite, repressed pattern.

THCA, LUAD, and KIRC are the cancer types where RUNX2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RUNX2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	IV	+2.215	<.001	11	view →
LUAD	Male	III,IV	+1.741	<.001	11	view →
KIRC	Male	IV	+1.220	<.001	11	view →
LUSC	Female	All	+1.399	<.001	7	view →
BRCA	All	III,IV	+1.282	<.001	6	view →
BLCA	All	All	+0.949	.006	6	view →
STAD	All	All	+0.831	<.001	4	view →
ESCA	All	All	+1.388	.001	3	view →
HNSC	All	All	+0.539	.014	3	view →
PAAD	All	All	+0.694	.030	2	view →
UCEC	All	All	+0.588	.031	2	view →
KIRP	All	All	+0.528	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

RUNX2–THCA

Open the THCA breakdown →